A detailed history of Qube Research & Technologies LTD transactions in Myriad Genetics Inc stock. As of the latest transaction made, Qube Research & Technologies LTD holds 70,777 shares of MYGN stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70,777
Holding current value
$2 Million
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$17.98 - $25.47 $1.27 Million - $1.8 Million
70,777 New
70,777 $1.73 Million
Q4 2023

Feb 13, 2024

SELL
$13.91 - $21.32 $1.56 Million - $2.4 Million
-112,483 Reduced 85.5%
19,070 $364,000
Q3 2023

Nov 13, 2023

BUY
$15.99 - $23.22 $1.81 Million - $2.62 Million
113,000 Added 609.07%
131,553 $2.11 Million
Q2 2023

Aug 14, 2023

BUY
$17.56 - $23.76 $325,790 - $440,819
18,553 New
18,553 $430,000
Q2 2022

Aug 15, 2022

BUY
$16.45 - $25.88 $296,511 - $466,487
18,025 New
18,025 $328,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $2.28B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.